Results 151 to 160 of about 2,123 (172)

Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study

EClinicalMedicine, 2023
Howard Sofen
exaly  

Prurigo nodularis

Der Hautarzt, 2014
S. Ständer, T. Mettang
openaire   +1 more source

Prurigo Nodularis

2016
Hugh Morris Gloster, Lauren E. Gebauer, Rachel L. Mistur   +2 more
  +4 more sources

Health-related quality of life and economic burden of prurigo nodularis

Journal of the American Academy of Dermatology, 2022
Katherine A Whang, Thomas K Le, Raveena Khanna   +2 more
exaly  

Increased IL-31 expression in serum and tissue protein in prurigo nodularis

Therapeutic Advances in Chronic Disease, 2022
Suteeraporn Chaowattanapanit, Rachot Wongjirattikarn, Nipon Chaisuriya   +2 more
exaly  

Dupilumab as promising treatment for prurigo nodularis: current evidences

Journal of Dermatological Treatment, 2022
Ludovica Toffoli, Eleonora Farinazzo, Enrico Zelin   +2 more
exaly  

Prurigo Nodularis: Moving Forward

Cutis, 2023
Ailish, Hanly, Kalman L, Watsky
openaire   +2 more sources

Prurigo nodularis: an update on etiopathogenesis and therapy

Journal of Dermatological Treatment, 2013
Giampiero Girolomoni, Gianpaolo Tessari   +1 more
exaly  

Ethnic differences and comorbidities of 909 prurigo nodularis patients

Journal of the American Academy of Dermatology, 2018
Emily Boozalis, Olive Tang, Shivani Patel   +2 more
exaly  

Prurigo Nodularis

2017
openaire   +2 more sources